Pages that link to "Q38827756"

The following pages link to Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus (Q38827756):

Displaying 41 items.

• Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice (Q26741860) (← links)
• Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial (Q33556240) (← links)
• Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cot (Q38376619) (← links)
• Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. (Q38658251) (← links)
• The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease (Q38679997) (← links)
• Implications of the EMPA-REG Trial for Clinical Care and Research (Q38798623) (← links)
• Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study (Q38903825) (← links)
• SGLT2 Inhibitors: Benefit/Risk Balance (Q38931842) (← links)
• Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect (Q38978384) (← links)
• Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies (Q39000587) (← links)
• Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. (Q39096331) (← links)
• Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes (Q39170860) (← links)
• Diabetes and heart failure : Update 2017 (Q40249021) (← links)
• Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome (Q41849079) (← links)
• Metabolic cardiomyopathies - fighting the next epidemic (Q42050369) (← links)
• SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. (Q47095186) (← links)
• Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials (Q47614541) (← links)
• Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis (Q47652080) (← links)
• Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus. (Q47672213) (← links)
• Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential (Q47726421) (← links)
• Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. (Q51382208) (← links)
• Cardiovascular effects of sodium glucose cotransporter 2 inhibitors. (Q52562709) (← links)
• [Diabetology as an interdisciplinary challenge]. (Q52713206) (← links)
• Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. (Q55421028) (← links)
• Drug Targets for Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach and Review of Contemporary Clinical Trials (Q57293272) (← links)
• Empagliflozin directly improves diastolic function in human heart failure (Q57453150) (← links)
• Revisiting the Diabetes-Heart Failure Connection (Q57807757) (← links)
• Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials (Q64066189) (← links)
• Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes (Q64084596) (← links)
• How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial (Q64101440) (← links)
• Clinical implications of cardiovascular outcome trials in type 2 diabetes (Q64244781) (← links)
• Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study (Q88142916) (← links)
• Revascularization in stable coronary disease: evidence and uncertainties (Q88355743) (← links)
• The optimal blood pressure target in diabetes mellitus: a quest coming to an end? (Q89207744) (← links)
• Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors (Q89506074) (← links)
• Clinical evidence and treatment requirements related to heart failure in type 2 diabetes mellitus (Q90156316) (← links)
• Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model (Q90174849) (← links)
• Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction (Q91593292) (← links)
• Diallyl trisulfide attenuates hyperglycemia-induced endothelial apoptosis by inhibition of Drp1-mediated mitochondrial fission (Q92209786) (← links)
• Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come (Q92327319) (← links)
• Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis (Q92857378) (← links)